Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amgen, Inc.
There are fewer than a handful of prescription video game digital therapeutics with regulatory clearance, but gamification in patient care is proving its worth as a novel way of treating a range of conditions, from vision loss to dyslexia and ADHD. Now, the onus is on lawmakers and insurers to create a clear path towards reimbursement.
Bristol Myers Squibb brought the last of nine new drugs to market last year – all needed to help it overcome three big losses of exclusivity this decade – so the focus this year is commercial execution.
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Amgen Astellas BioPharma K.K.
- Amgen K.K.
- BioVex Group
- Catherex, Inc.
- ChemoCentryx, Inc.
- deCODE Genetics
- Dezima Pharma B.V.
- Five Prime Therapeutics, Inc.
- Immunex Corporation
- KAI Pharmaceuticals
- Kirin-Amgen Inc.
- Laboratorio Quimico Farmaceutico Bergamo Ltd
- Micromet, Inc. (CancerVax Corporation)
- Nuevolution AB
- Nuevolution A/S
- Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
- Saga Investments LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.